Eric J Schultz
Overview
Explore the profile of Eric J Schultz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
96
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Peczkowski K, Rastogi N, Lowe J, Floyd K, Schultz E, Karaze T, et al.
Front Physiol
. 2022 Jan;
12:820245.
PMID: 35069268
[This corrects the article DOI: 10.3389/fphys.2020.568909.].
2.
Mashali M, Saad N, Canan B, Elnakish M, Milani-Nejad N, Chung J, et al.
J Mol Cell Cardiol
. 2021 Mar;
156:7-19.
PMID: 33766524
Background: Heart failure (HF) is associated with highly significant morbidity, mortality, and health care costs. Despite the significant advances in therapies and prevention, HF remains associated with poor clinical outcomes....
3.
Peczkowski K, Rastogi N, Lowe J, Floyd K, Schultz E, Karaze T, et al.
Front Physiol
. 2020 Oct;
11:568909.
PMID: 33101056
Duchenne muscular dystrophy (DMD) is an X-linked disorder caused by the lack of functional dystrophin protein. In muscular dystrophy preclinical research, it is pertinent to analyze the force of the...
4.
Wickerham A, Schultz E, Lewine E
JAMA Intern Med
. 2017 Oct;
177(11):1670-1671.
PMID: 28975225
No abstract available.
5.
Milani-Nejad N, Schultz E, Slabaugh J, Janssen P, Rafael-Fortney J
Front Physiol
. 2016 Dec;
7:539.
PMID: 27999547
Mutations in several members of the dystrophin glycoprotein complex lead to skeletal and cardiomyopathies. Cardiac care for these muscular dystrophies consists of management of symptoms with standard heart medications after...
6.
Lowe J, Floyd K, Rastogi N, Schultz E, Chadwick J, Swager S, et al.
J Neuromuscul Dis
. 2016 Nov;
3(3):395-404.
PMID: 27822449
Background: Combined treatment with an angiotensin-converting enzyme inhibitor and a mineralocorticoid receptor (MR) antagonist improved cardiac and skeletal muscle function and pathology in a mouse model of Duchenne muscular dystrophy....
7.
Lowe J, Wodarcyk A, Floyd K, Rastogi N, Schultz E, Swager S, et al.
J Neuromuscul Dis
. 2016 Apr;
2(3):257-268.
PMID: 27110493
Background: Angiotensin converting enzyme inhibitors (ACEi) are the current standard of care treatment for cardiac dysfunction in Duchenne muscular dystrophy patients. We previously showed treatment with an ACEi plus mineralocorticoid...
8.
Canan B, Haizlip K, Xu Y, Monasky M, Hiranandani N, Milani-Nejad N, et al.
J Appl Physiol (1985)
. 2016 Jan;
120(8):817-24.
PMID: 26823341
It is well known that moderate exercise training elicits a small increase in ventricular mass (i.e., a physiological hypertrophy) that has many beneficial effects on overall cardiac health. It is...
9.
Elnakish M, Schultz E, Gearinger R, Saad N, Rastogi N, Ahmed A, et al.
Free Radic Biol Med
. 2015 Mar;
83:252-61.
PMID: 25795514
Thyroid hormones are key regulators of basal metabolic state and oxidative metabolism. Hyperthyroidism has been reported to cause significant alterations in hemodynamics, and in cardiac and diaphragm muscle functions, all...
10.
Janssen P, Murray J, Schill K, Rastogi N, Schultz E, Tran T, et al.
PLoS One
. 2014 Feb;
9(2):e88360.
PMID: 24551095
Duchenne muscular dystrophy (DMD) is an inherited disease that causes striated muscle weakness. Recently, we showed therapeutic effects of the combination of lisinopril (L), an angiotensin converting enzyme (ACE) inhibitor,...